Skip to main content
. Author manuscript; available in PMC: 2014 Aug 26.
Published in final edited form as: Target Oncol. 2013 Jan 9;8(3):203–209. doi: 10.1007/s11523-012-0252-7

Table 2.

First- and second-line overall response rates (RR) for each targeted therapy

Targeted therapy First-line RR Second-line RR
Sunitinib 31 % (69/226) 18 % (22/125)
Sorafenib 14 % (19/139) 6 % (11/171)
Bevacizumab 10 % (6/59) 0 % (0/20)
Axitinib N/A 36 % (4/11)
Pazopanib N/A 0 % (0/2)

Patient numbers are small and comparisons should not be made. Denominators are based on the availability of response information for each patient